Boston Trust Walden Corp Acquires 94,750 Shares of Jazz Pharmaceuticals PLC $JAZZ

Boston Trust Walden Corp lifted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 24.1% in the 1st quarter, Holdings Channel reports. The firm owned 488,661 shares of the specialty pharmaceutical company’s stock after acquiring an additional 94,750 shares during the period. Jazz Pharmaceuticals comprises 0.8% of Boston Trust Walden Corp’s investment portfolio, making the stock its 29th largest holding. Boston Trust Walden Corp’s holdings in Jazz Pharmaceuticals were worth $92,381,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Royal Bank of Canada increased its stake in Jazz Pharmaceuticals by 96.5% in the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after acquiring an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after buying an additional 209,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after buying an additional 7,954 shares in the last quarter. Focus Partners Wealth lifted its position in Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after buying an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $188.00 to $307.00 in a research report on Tuesday, May 19th. Barclays boosted their price objective on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Wells Fargo & Company upped their price objective on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Robert W. Baird set a $252.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $245.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $246.06.

Insider Activity

In related news, Director Rick E. Winningham sold 2,741 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director directly owned 9,567 shares of the company’s stock, valued at $2,311,100.19. This trade represents a 22.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the transaction, the executive vice president owned 51,549 shares in the company, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,098 shares of company stock worth $1,689,086 over the last ninety days. 4.10% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Up 2.5%

Shares of Jazz Pharmaceuticals stock opened at $243.47 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $243.81. The company’s 50 day moving average price is $227.55 and its 200-day moving average price is $194.91. The stock has a market capitalization of $15.29 billion, a price-to-earnings ratio of -12,167.42, a P/E/G ratio of 0.21 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.